With Action Date Imminent, Biogen's Aducanumab Invokes Hope and Skepticism

The U.S. Food and Drug Administration (FDA) has a target action date of June 7 for Biogen’s aducanumab for Alzheimer’s disease. The short-term fortunes are at stake. If the FDA approves, shares are likely to soar; if rejected, likely to plunge, at least temporarily.